BLAINJECTIONINJECTABLEPriority Review
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
254
Data completeness
6/8 — Strong
Priority Review
IMFINZI (durvalumab) by AstraZeneca is programmed death ligand-1 antagonists [moa]. Approved for non-small cell lung cancer, hepatocellular carcinoma. First approved in 2017.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMFINZI (durvalumab) is a monoclonal antibody that blocks programmed death ligand-1 (PD-L1), an immune checkpoint inhibitor developed by AstraZeneca. It was approved by the FDA on May 1, 2017, and works by removing the inhibitory signal that cancer cells use to evade the immune system, thereby enhancing anti-tumor immunity. The drug is administered via intravenous injection and represents a key player in the immuno-oncology landscape for multiple cancer indications.
$0.0BPart D
Mechanism of Action
Programmed Death Ligand-1 Antagonists
Pharmacologic Class:
Programmed Death Ligand-1 Blocker
Indications (2)
Worked on IMFINZI at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.